Femasys reports Q2 EPS (21c), consensus (17c)

Reports Q2 revenue $221,484, consensus $780,000. “The recruitment and subsequent onboarding of our commercial team, consisting of highly qualified professionals with specific expertise in women’s health is complete and our team has recently begun actively marketing our products in the U.S.. We believe that our novel fertility solution FemaSeed, which demonstrated pregnancy rates more than double the historic intrauterine insemination pregnancy rates for male factor infertility, is an improved alternative and a viable option prior to in vitro fertilization that is considerably more financially and emotionally burdensome. As we await announcement of published data for the FemaSeed prospective multi-center pivotal trial, we are actively prioritizing our U.S. efforts and concurrently identifying strategic distribution partners in Europe,” said Femasys’ CEO Kathy Lee-Sepsick.